News and analysis on disease research and diagnostics.
The Voyage study is designed to enroll more than 150,000 people and will follow participants for at least seven years.
The investment banks cited the company's access to proprietary technology and the potential $5 billion market for Exagen's testing options as reasons for its Outperform rating.
The companies will develop an assay to guide treatment with a type of radiopharmaceutical therapy in patients with these rare tumors.
The company said the revenue growth was driven by growing international demand for its noninvasive prenatal testing products and services.
The test, which detects antibodies to Ebola virus from whole-blood samples and cadaveric oral fluid, was also granted breakthrough device designation.
